ArticleMolecular medicine (Cambridge, Mass.)2025
PARP3 promotes macrophage inflammation via mono ADP ribosylation of Ppia Glu140.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities.Cancers · 2025Review
- Discovery and Mechanistic Elucidation of Glycyrrhizic Acid Composite Gel in Promoting Wound Healing: A Modernized Study Based on Shengji Yuhong Ointment.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAcute lung injury (ALI) carries significant mortality with limited targeted therapies. Macrophages drive early inflammatory propagation in ALI, exacerbating pulmonary inflammation. While ADP-ribosylation is a dynamic and reversible post-translational modification (PTM) associated with inflammatory diseases, its role in macrophage-mediated inflammation remains unclear.
methodsMurine ALI model was established via intratracheal instillation with lipopolysaccharide (LPS). The ALI lung tissues and cultured mouse macrophage line (RAW264.7) treated with LPS were used to assess the expression of poly ADP-ribose polymerases (Parps). RNA sequencing (RNA-seq) identified differentially expressed genes (DEGs) following Parp3 knockdown (siParp3) in LPS-stimulated RAW264.7 cells, with subsequent pathway analysis was via transcription factors (TFs) profiling and gene ontology (GO) enrichment. In RAW264.7 cells, Parp3 and peptidyl-prolyl cis-trans isomerase A (Ppia) was modulated by siRNA or plasmid transfection. PARP3-Ppia interaction and ADP-ribosylation were assessed by immunoprecipitation. Modification alterations due to mutations at Ppia modification sites were assessed by immunoprecipitation. Enzyme-linked immune sorbent assay (ELISA) was used to quantify Ppia secretion. A mouse ALI model was used to evaluate the lung-protective and therapeutic effects of PARP3 inhibitor ME0328 by detecting inflammatory cytokines, phosphorylation of p65 and lung histopathology.
resultsLPS induced the expression of Parp3 in RAW264.7 cells and ALI lung tissues, correlating with elevated inflammatory cytokines. The 52 overlapping DEGs were mainly enriched in Toll-like receptor (TLR) signaling pathway. PARP3 promoted inflammation via NF-κB activation. ME0328 blocked NF-κB pathway activation in RAW264.7 cells and lung tissues. Immunoprecipitation confirmed that PARP3 interacted with Ppia. Ppia was modified with mono ADP-ribosylation. Ppia-E140 was the most inflammation related modification site. The mutation of E140 inhibited inflammatory response, mono ADP-ribosylation and secretion of Ppia. In vivo, ME0328 reduced inflammatory response, alleviated pulmonary edema and mitigated histopathological damage.
conclusionsWe identified the NF-κB as the downstream signaling pathway mediated by Ppia for PARP3 to promote macrophage inflammation. ME0328 alleviated pulmonary inflammation through the NF-κB signaling pathway. Our findings provide evidence that macrophage inflammation is associated with the mono ADP-ribosylation on Ppia. Understanding mono ADP-ribosylation regulation in macrophage from ALI may provide insight into the pro-inflammatory mechanisms and opportunities for effective therapeutic to treat acute lung injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.